Back to top

Image: Bigstock

Moody's (MCO) Beats on Q2 Earnings and Revenue Estimates

Read MoreHide Full Article

Have you been eager to see how Moody's Corporation (MCO - Free Report) , performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this NY-based credit rating giant’s earnings release this morning:

An Earnings Beat

Moody’s reported adjusted earnings were $2.04 per share, which beat the Zacks Consensus Estimate of $1.88.

Results were primarily driven by a rise in revenues.

How Was the Estimate Revision Trend?

You should note that the earnings estimate for Moody’s depicted bullish stance prior to the earnings release. The Zacks Consensus Estimate rose marginally over the last 30 days.

Further, Moody’s has a decent earnings surprise history.

Moody's Corporation Price and EPS Surprise

Overall, the company surpassed the Zacks Consensus Estimate by an average of 9.9% in the trailing four quarters.

Revenue Came in Higher than Expected

Moody’s reported revenues of $1.18 billion, beating the Zacks Consensus Estimate of $1.15 billion. Also, revenues grew 17% year over year.

Key Takeaways
 

  • After taking into consideration amortization of all acquisition-related intangible assets and acquisition-related expenses, net income attributable to Moody's Corporation was $376.2 million or $1.94 per share.
  • As of Jun 30, 2018, Moody’s had total cash, cash equivalents and short-term investments of $1.31 billion.
  • In the reported quarter, Moody’s returned $122.1 million to shareholders.
  • Moody’s affirmed expecting adjusted earnings in the range of $7.65-$7.85 per share in 2018.


What Zacks Rank Says

The estimate revisions that we discussed earlier have driven a Zacks Rank #3 (Hold) for Moody’s. However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. While the results apparently look favorable, it all depends on what sense the just-released report makes to the analysts.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Check back later for our full write up on this Moody’s earnings report!

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Moody's Corporation (MCO) - free report >>